| （単位：千ドル） | 2Q21 | 3Q21 | 1Q22 | 2Q22 | 3Q22 | 1Q23 | 2Q23 | 3Q23 | 1Q24 | 2Q24 | 3Q24 | 1Q25 | 2Q25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 研究開発費 | 10,906 | 12,944 | 24,155 | 20,876 | 23,758 | 25,605 | 26,477 | 23,091 | 25,055 | 22,649 | 20,350 | 21,076 | 17,370 |
| 営業費用 | 15,237 | 18,300 | 31,154 | 28,619 | 31,298 | 33,723 | 35,104 | 30,920 | 33,762 | 30,823 | 26,711 | 27,538 | 24,082 |
| 営業利益 | -15,237 | -18,300 | -31,154 | -28,619 | -31,298 | -33,723 | -35,104 | -30,920 | -33,762 | -30,823 | -26,711 | -27,538 | -24,082 |
| 経常（税引前）利益 | -15,210 | -18,262 | -31,056 | -28,397 | -30,696 | -31,737 | -33,269 | -29,143 | -32,228 | -29,431 | -25,634 | -26,864 | -23,283 |
| 純利益 | -15,210 | -18,262 | -31,056 | -28,397 | -30,696 | -31,700 | -33,269 | -29,143 | -32,200 | -29,431 | -25,634 | -26,864 | -23,283 |
| 一株あたり利益 | - | - | - | - | -0.74 | -0.43 | -0.45 | -0.39 | -0.4 | -0.34 | -0.3 | -0.24 | -0.14 |
| 希薄化後一株あたり利益 | - | - | - | - | -0.74 | -0.43 | -0.45 | -0.39 | -0.4 | -0.34 | -0.3 | -0.24 | -0.14 |
| EBITDA | - | - | - | - | - | - | - | - | - |